PSMA PET Ligands in Prostate Cancer: A Game‐changer?

Trends in Urology & Men's Health
doi 10.1002/tre.700
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Immunohistochemical Validation of PSMA-expression Measured by 68 Ga-Psma PET/CT in Primary Prostate Cancer

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2017English

Alpha-Pet for Prostate Cancer: Preclinical Investigation Using 149Tb-Psma-617

Scientific Reports
Multidisciplinary
2019English

MRI-guided Adaptive Radiotherapy; A “Game Changer” for Prostate Radiotherapy

International Journal of Radiation Oncology Biology Physics
OncologyRadiologyCancer ResearchRadiationNuclear MedicineImaging
2018English

The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2016English

Comparison of [18F]DCFPyL and [68Ga]Ga-Psma-Hbed-Cc for PSMA-PET Imaging in Patients With Relapsed Prostate Cancer

Molecular Imaging and Biology
Cancer ResearchNuclear MedicineRadiologyImagingOncology
2015English

Diagnostic Performance of 18f-Psma-1007 PET/CT in Patients With Biochemical Recurrent Prostate Cancer

European Journal of Nuclear Medicine and Molecular Imaging
MedicineNuclear MedicineRadiologyImaging
2018English

68Ga-Hbed-Cc-Psma PET/CT Versus Histopathology in Primary Localized Prostate Cancer: A Voxel-Wise Comparison

Theranostics
MedicineToxicologyPharmaceuticsPharmacology
2016English

68Ga-Psma Ligand PET/CT in Patients With Prostate Cancer: How We Review and Report

Cancer Imaging
Nuclear MedicineRadiologyUltrasound TechnologyOncologyRadiologicalImagingMedicine
2016English

Comparison of 68Ga-Psma-11 PET/CT With 11c-Acetate PET/CT in Re-Staging of Prostate Cancer Relapse

Scientific Reports
Multidisciplinary
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy